Suplementação com açaí (Euterpe Oleracea Martius) para o tratamento do zumbido crônico: efeitos na percepção, níveis de ansiedade e biomarcadores de metabolismo oxidativo

Oppitz, Sheila Jacques; Garcia, Michele Vargas; Bruno, Rubia Soares; Zemolin, Cleide Monteiro; Baptista, Bruna Olegário; Turra, Bárbara Osmarin; Cruz, Ivana Beatrice Mânica da; Silveira, Aron Ferreira da

doi:10.1590/2317-1782/20212021076

Cited by 8 publications

(5 citation statements)

References 21 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there was no significant difference with the placebo, probably due to a strong response in this arm. Another randomized controlled trial reported a 10.0-point reduction in THI score after 3 months' consumption of 100 mg of the higher antioxidant-rich extract of Euterpe oleracea martius (Açaí) once a day [32]. Overall, these results provide clinical evidence for the use of antioxidant molecules in tinnitus that should not be ignored.…”

Section: Discussionmentioning

confidence: 83%

“…THI score changes from baseline at 3 months was chosen as meaningful primary endpoint. The Tinnitus Handicap Inventory [22] and its French version [24] is a 25-item self-report measure to determine perceived tinnitus handicap severity which is classified as very mild (score 0-16), mild (score [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36], moderate (score 38-56), severe (score 58-76), and catastrophic (78-90). A change in score of at least seven points has been considered to denote reliable clinically significant improvement on the THI [26].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

AUDISTIM® Day/Night Alleviates Tinnitus-Related Handicap in Patients with Chronic Tinnitus: A Double-Blind Randomized Placebo-Controlled Trial

Portmann,

Esteve-Fraysse,

Frachet

et al. 2024

Audiology Research

View full text Add to dashboard Cite

The aim of this study is to evaluate the efficacy of taking a daily supplement based on active compounds (AUDISTIM® Day Night: A D/N) in alleviating tinnitus-related disability, as suggested by previous real-life studies. This double-blind randomized placebo-controlled study was conducted in adults with mild to severe tinnitus receiving a 3-month supplementation with A D/N (magnesium, vitamins, phytochemicals) or placebo (excipients without active ingredients). Tinnitus-related handicap (THI), psychological stress (MSP-9), and sleep quality (PSQI) were assessed at baseline and during intervention, perceived impression of tinnitus improvement at the end of the follow-up. The full set analysis included 114 patients (59 A D/N, 55 placebo) aged 53.8 ± 11.4 years, 58% women, with fluctuating (45%) or permanent (55%) tinnitus from 9.3 ± 9.4 years. A D/N supplementation led to greater changes in THI (−13.2 ± 16.0 vs. −6.2 ± 14.4, p = 0.0158, Cohen’s d = 0.44) at 3 months (primary outcome), especially with continuous tinnitus (−15.0 ± 16.3 vs. −4.6 ± 12.8, p = 0.0065), and, to a lesser extent, at 1 month (−9.8 ± 13.1 for A vs. −4.3 ± 12.1, p = 0.0213). PSQI significantly improved over time in both groups, but MSP-9 only with A D/N. In lines with previous observational studies, both clinical (THI score > 7 pts) and statistical (vs. placebo) improvement, more pronounced in permanent tinnitus, demonstrate the effectiveness of the combination of active compounds and support its use in the management of mild to severe tinnitus.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Methodsmentioning

confidence: 99%

AUDISTIM® Day/Night Alleviates Tinnitus-Related Handicap in Patients with Chronic Tinnitus: A Double-Blind Randomized Placebo-Controlled Trial

Portmann,

Esteve-Fraysse,

Frachet

et al. 2024

Audiology Research

View full text Add to dashboard Cite

show abstract

“…However, there was no significant difference with placebo, probably due to a strong response in this arm. Another randomized controlled trial reported a 10.0-point reduction in THI score after 3 months' consumption of 100 mg of the higher antioxidant-rich extract of Euterpe oleracea martius (Açaí) once a day [32]. Overall, these results provide clinical evidence for antioxidant molecules in tinnitus that should not be ignored.…”

Section: Discussionmentioning

confidence: 84%

AUDISTIM® Day/Night Alleviates Tinnitus-Related Handicap in Patients with Chronic Tinnitus: A Double-Blind Randomized Placebo-Controlled Trial

PORTMANN,

ESTEVE-FRAYSSE,

FRACHET

et al. 2024

Preprint

View full text Add to dashboard Cite

The aim of this study is to evaluate the efficacy of taking a daily supplement based on active compounds (AUDISTIM® Day Night: A D/N) in alleviating tinnitus-related disability, as suggested by previous real-life studies. This double-blind randomized placebo-controlled study was conducted in adult with mild to severe tinnitus receiving a 3 month-supplementation. Tinnitus-related handicap (THI), psychological stress (MSP-9) and sleep quality (PSQI) were assessed at baseline and during intervention, perceived impression of tinnitus improvement at the end of the follow-up. The full set analysis included 114 patients (59 A D/N, 55 placebo) aged 53.8±11.4 years, 58% women, with fluctuating (45%) or permanent (55%) tinnitus from 9.3±9.4 years. A D/N supplementation led to greater changes in THI (-13.2±16.0 vs -6.2±14.4, p=0.0158, Cohen’s d=0.44) at 3 months, especially with continuous tinnitus (-15.0±16.3 vs -4.6±12.8, p=0.0065), and, to a lesser extent, at 1 month (-9.8±13.1 for A vs -4.3±12.1, p=0.0213). PSQI significantly improved over time in both groups, MSP-9 only with A D/N. In lines with previous observational studies, both clinical (THI score &gt; 7 pts) and statistical (vs. placebo) improvement, more pronounced in permanent tinnitus, demonstrate the effectiveness of the combination of active compounds and support its use in the management of mild to severe tinnitus.

show abstract

“…Antioxidant therapy in patients with idiopathic tinnitus could reduce oxidative stress and damage to the inner ear, also reducing tinnitus loudness and discomfort. However, research data on the efficacy of antioxidant supplementation in tinnitus are scarce and conflicting, although there are some recent reports that show tinnitus improvement after treatment with antioxidants ( Procházková et al, 2018 ; Oppitz et al, 2022 ). Additionally, emerging evidence suggests that neuroinflammation may play a large role in the development of tinnitus and the influence of various proinflammatory cytokines such as TNF-α, IL-6, β-2GP1 and IL-1 has been described.…”

Section: Discussionmentioning

confidence: 99%

The effect of MemoVigor 2 on recent-onset idiopathic tinnitus: a randomized double-blind placebo-controlled clinical trial

Balatsouras,

Papitsi,

Koukoutsis

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Tinnitus is a common symptom associated with the conscious perception of sound in the absence of a corresponding external or internal sound source, which can severely impact quality of life. Because of the current limited understanding of the precise pathophysiological mechanism of idiopathic tinnitus, no curable treatment has been attained yet. A food supplement trading as MemoVigor 2, which contains a combination of therapeutic ingredients with mainly antioxidant activity, has been used in the treatment of tinnitus. The objective of our study was to evaluate the effectiveness of MemoVigor 2 in the treatment of recent-onset idiopathic tinnitus.Methods: In a prospective single-centre randomized, double-blind, placebo-controlled clinical trial we studied 204 patients with idiopathic tinnitus divided into two groups: 104 patients who received MemoVigor 2 and 100 patients treated with placebo. To evaluate changes in tinnitus we used (1) audiometry/tympanometry; (2) specific measures of tinnitus perception, including tinnitus pitch, loudness at tinnitus pitch, loudness at 1 kHz, minimum masking level, and residual inhibition; (3) questionnaires of tinnitus handicap inventory, mini tinnitus questionnaire and patients’ global impression of change. All patients underwent this test battery at the beginning of the study and in a repeat post-3-month session.Results: All tinnitus measures, including pitch, loudness, minimum masking level and residual inhibition improved significantly in the intervention group. Most of these measures improved in the placebo group too, but in a lesser degree. All questionnaire scores diminished significantly in both groups, but the degree of decrease was greater in the intervention group. The participants’ tinnitus outcome reported after treatment using the patients’ global impression of change score differed significantly between the two groups, with greater improvement observed in the intervention group.Conclusion: We found that the use of MemoVigor 2 improved recent-onset tinnitus, as proved by a set of tests performed for its evaluation, including audiometric measures, specific measures of tinnitus perception and tinnitus questionnaires. Tinnitus in the placebo group improved too, but to a lesser degree.Clinical Trial Registration: isrctn.com, Identifier ISRCTN16025480

show abstract

Suplementação com açaí (Euterpe Oleracea Martius) para o tratamento do zumbido crônico: efeitos na percepção, níveis de ansiedade e biomarcadores de metabolismo oxidativo

Cited by 8 publications

References 21 publications

AUDISTIM® Day/Night Alleviates Tinnitus-Related Handicap in Patients with Chronic Tinnitus: A Double-Blind Randomized Placebo-Controlled Trial

AUDISTIM® Day/Night Alleviates Tinnitus-Related Handicap in Patients with Chronic Tinnitus: A Double-Blind Randomized Placebo-Controlled Trial

AUDISTIM® Day/Night Alleviates Tinnitus-Related Handicap in Patients with Chronic Tinnitus: A Double-Blind Randomized Placebo-Controlled Trial

The effect of MemoVigor 2 on recent-onset idiopathic tinnitus: a randomized double-blind placebo-controlled clinical trial

Contact Info

Product

Resources

About